Prof Phil Robinson
Prof Phil Robinson
Details
Role
Honorary Fellow Manager
Research area
Infection, Immunity and Global Health
Group
Respiratory
Contact
Available for student supervision
Professor Robinson is the Director of Respiratory and Sleep Medicine at The Royal Children's Hospital (RCH). Professor Robinson completed his basic paediatric training at RCH before undertaking three years of advanced training in Paediatric Respiratory Medicine at RCH, then completing two years of post-doctoral study at the Pulmonary Research Laboratory of the University of British Columbia in Vancouver, Canada. He was appointed a consultant in Respiratory Medicine at The Royal Children's Hospital in 1991.
He was awarded a PhD from the University of Melbourne in 2003 for his work on the effect of in-utero cigarette smoke exposure on antenatal lung development. Phil was Director of Cystic Fibrosis (CF) clinical services from 1998 to 2014 helped establish the Royal Children's Cystic Fibrosis Research Trust and remains the Trust's medical chairman. He was the paediatric editor of the first edition of the Australian Standards of Care for Cystic Fibrosis.
In 2014 he established the state's diagnostic service for Primary Ciliary Dyskinesia and an allied clinical bronchiectasis service in 2017. He heads a respiratory drug trial unit involved in over 80 multinational drug trials of asthma, Cystic Fibrosis, PCD and RSV bronchiolitis.
His main area of clinical and research interest is in suppurative lung disease particularly CF and PCD, particularly lung imaging of these conditions.
He was awarded a PhD from the University of Melbourne in 2003 for his work on the effect of in-utero cigarette smoke exposure on antenatal lung development. Phil was Director of Cystic Fibrosis (CF) clinical services from 1998 to 2014 helped establish the Royal Children's Cystic Fibrosis Research Trust and remains the Trust's medical chairman. He was the paediatric editor of the first edition of the Australian Standards of Care for Cystic Fibrosis.
In 2014 he established the state's diagnostic service for Primary Ciliary Dyskinesia and an allied clinical bronchiectasis service in 2017. He heads a respiratory drug trial unit involved in over 80 multinational drug trials of asthma, Cystic Fibrosis, PCD and RSV bronchiolitis.
His main area of clinical and research interest is in suppurative lung disease particularly CF and PCD, particularly lung imaging of these conditions.
Professor Robinson is the Director of Respiratory and Sleep Medicine at The Royal Children's Hospital (RCH). Professor Robinson completed his basic paediatric training at RCH before undertaking three years of advanced training in Paediatric...
Professor Robinson is the Director of Respiratory and Sleep Medicine at The Royal Children's Hospital (RCH). Professor Robinson completed his basic paediatric training at RCH before undertaking three years of advanced training in Paediatric Respiratory Medicine at RCH, then completing two years of post-doctoral study at the Pulmonary Research Laboratory of the University of British Columbia in Vancouver, Canada. He was appointed a consultant in Respiratory Medicine at The Royal Children's Hospital in 1991.
He was awarded a PhD from the University of Melbourne in 2003 for his work on the effect of in-utero cigarette smoke exposure on antenatal lung development. Phil was Director of Cystic Fibrosis (CF) clinical services from 1998 to 2014 helped establish the Royal Children's Cystic Fibrosis Research Trust and remains the Trust's medical chairman. He was the paediatric editor of the first edition of the Australian Standards of Care for Cystic Fibrosis.
In 2014 he established the state's diagnostic service for Primary Ciliary Dyskinesia and an allied clinical bronchiectasis service in 2017. He heads a respiratory drug trial unit involved in over 80 multinational drug trials of asthma, Cystic Fibrosis, PCD and RSV bronchiolitis.
His main area of clinical and research interest is in suppurative lung disease particularly CF and PCD, particularly lung imaging of these conditions.
He was awarded a PhD from the University of Melbourne in 2003 for his work on the effect of in-utero cigarette smoke exposure on antenatal lung development. Phil was Director of Cystic Fibrosis (CF) clinical services from 1998 to 2014 helped establish the Royal Children's Cystic Fibrosis Research Trust and remains the Trust's medical chairman. He was the paediatric editor of the first edition of the Australian Standards of Care for Cystic Fibrosis.
In 2014 he established the state's diagnostic service for Primary Ciliary Dyskinesia and an allied clinical bronchiectasis service in 2017. He heads a respiratory drug trial unit involved in over 80 multinational drug trials of asthma, Cystic Fibrosis, PCD and RSV bronchiolitis.
His main area of clinical and research interest is in suppurative lung disease particularly CF and PCD, particularly lung imaging of these conditions.
Top Publications
- Suryadinata, R, Bennett-Wood, V, McKinnon, M, Vandeleur, M, Robinson, P. Repetitive Exposure to Nicotine-Free Vaping Impairs Airway Defences and Delays Recovery.. Lung 204(1) : 8 2026 view publication
- Fabri, L, Shanthikumar, S, Robinson, P. SUBSEGMENTAL LOBAR COLLAPSE AS AN EARLY RADIOLOGIC SIGN OF PRIMARY CILIARY DYSKINESIA. Respirology 25(S1) : 2026 view publication
- Wang, KCW, Robinson, PJ, James, AL, Noble, PB, Elliot, JG. Increased Airway Smooth Muscle Shortening Is Associated With an Earlier Age of Sudden Unexpected Death in Infancy.. J Paediatr Child Health 61(11) : 1818 -1820 2025 view publication
- Harwood, KH, Duffull, S, Shanthikumar, S, Lei, A, Ranganathan, S, Robinson, P, Sandaradura, I, Lai, T, Gwee, A. Personalized tobramycin dosing in children with cystic fibrosis: an AUC24-guided approach.. Antimicrob Agents Chemother 69(9) : e0027825 2025 view publication
- Suryadinata, R, Martinello, P, Bennett-Wood, V, Robinson, P. Heterozygous cis HYDIN mutations cause primary ciliary dyskinesia.. Med 6(1) : 100508 2025 view publication
Page 1 of 25
Career information
Share //
